undruggable targets

IPO

Biotech

GPCR firm Septerna files for IPO on strength of preclinical data

The GPCR specialist is asking investors to fund its lead hypoparathyroidism candidate through phase 2 before it shares initial data in humans.

Nick Paul Taylor Oct 3, 2024 6:00am

An artists illustration of a KRAS G12C mutation in non-small cell lung cancer

AACR: KRAS inhibitors pop in preclinical data debuts

Apr 11, 2024 4:30am

Eli Lilly

Lilly inks backloaded $660M Prism drug discovery pact

Nov 29, 2023 5:53am

Glue

Roche pays $50M to Monte Rosa in latest molecular glue deal

Oct 17, 2023 8:25am

pigs piggy bank bank money cash

Sanofi pays $125M, offers up to $1.2B biobucks for Recludix deal

Jul 20, 2023 8:00am

Phoro of a couple at the top of a mountain during sunrise or sunset

Ginkgo, Boehringer Ingelheim team up on $406M discovery pact

May 8, 2023 7:00am